New pregnancy registry aims to uncover risks of MS drug ZEPOSIA for mothers and babies
NCT ID NCT05170126
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 1,200 pregnant women with multiple sclerosis who take the drug ZEPOSIA (ozanimod). Researchers will track health outcomes for mothers and their babies, such as birth defects and pregnancy complications. The goal is to help patients and doctors make informed decisions about using this medication during pregnancy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Evidera
RECRUITINGBethesda, Maryland, 20814, United States
Contact
-
Evidera INC.
RECRUITINGBethesda, Maryland, 20814, United States
Contact
-
Marienhospital Herne, Klinikum Der Ruhr-Universitaet Bochum
RECRUITINGHerne, 44625, Germany
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Simple chin and neck exercises put to the test for MS swallowing problems
- Could a daily walk shield the brain's wiring in aging MS patients?
- Brain boot camp: can a memory-training program sharpen thinking in multiple sclerosis?
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Brain training without drugs: can imagining movement ease MS pain?